Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Chronic kidney disease (CKD) remains a major and evolving healthcare challenge. At the same time, the treatment landscape is becoming increasingly competitive.

This GlobalData report provides a comprehensive view of the CKD therapeutics market across the seven major markets (7MM): the US, five major European markets, and Japan.

GlobalData estimates that CKD therapeutics sales across the 7MM will reach approximately $4.3 billion in 2025. The market is forecast to reach $10.9 billion by 2035, representing a CAGR of 9.8% over the forecast period.

Therefore, the report can help you assess where market growth may come from and which emerging therapies could influence the future treatment landscape.

The analysis combines market forecasting, epidemiology, disease management, pipeline assessment, competitive analysis, unmet needs, and physician insights.

CKD Market Forecast 2025–2035: Identify the Key Growth Opportunities

The CKD market is expected to experience substantial change through 2035.

Several factors may contribute to this growth, including:

• Expansion of GLP-1 receptor agonists into kidney-related indications
• Launches of seven oral pipeline agents
• Launches of six injectable pipeline agents
• Increasing CKD prevalence
• Continued innovation across new mechanisms of action
• Greater focus on disease-modifying treatment approaches

However, market expansion may also face significant barriers.

High therapy costs could constrain adoption. In addition, physicians may face increasing complexity when positioning and sequencing therapies.

Generic CKD treatments may also continue to limit uptake of higher-priced branded therapies, particularly in earlier lines of treatment.

The report helps you assess both sides of this market equation: where growth may emerge and what could constrain commercial opportunity.

CKD Pipeline Analysis: Evaluate Emerging Drugs and New Mechanisms

The CKD pipeline is becoming increasingly diverse.

This report provides a detailed assessment of therapies in clinical development. It also profiles promising late-stage candidates that could influence the future treatment landscape.

You can use the analysis to:

• Track emerging CKD therapies
• Assess new mechanisms of action
• Identify late-stage pipeline candidates
• Understand potential competitive threats
• Evaluate pipeline strength across companies
• Support business development and licensing assessments
• Monitor changes in the future treatment paradigm

Moreover, pipeline valuation and competitive assessment provide additional context for evaluating the potential commercial impact of emerging therapies.

Scope

The report provides a detailed 2025-2035 epidemiological forecast across the 7MM.

It covers:

• Total prevalent CKD cases
• CKD prevalence by disease stage
• Diagnosed prevalent cases
• Age-specific prevalence
• Sex-specific prevalence
• Dialysis-dependent populations
• Historical and global epidemiological trends
• Risk factors and comorbidities

As a result, you can connect changes in the CKD patient population with potential treatment demand.

The analysis also outlines its forecast methodology, assumptions, sources, strengths, and limitations. This provides useful context when interpreting the epidemiological projections.

CKD Unmet Needs: Identify Opportunities for New Treatments

Despite established treatment options, important unmet needs remain.

The report examines opportunities across areas including:

• Drug cost and market access
• Patient compliance
• Clinical trial endpoints
• Patient selection
• Patient education and awareness

These areas can help you understand where future innovation may create meaningful differentiation.

For example, improving treatment convenience or patient compliance may become increasingly important as more therapeutic options enter the market.

Similarly, understanding clinical trial endpoints and patient selection can help inform R&D strategy and development planning.

CKD Disease Management and Physician Insights

Understanding clinical practice is as important as understanding the pipeline.

The report examines CKD diagnosis and treatment pathways. It also incorporates key opinion leader insights and prescriber survey findings.

You can use these insights to better understand:

• Current disease management approaches
• Treatment decision-making
• Physician perspectives
• Areas of unmet need
• Potential barriers to adoption
• Changing treatment preferences

This provides an additional layer of market intelligence beyond quantitative market forecasts.

Key Highlights

GlobalData estimates the sales of CKD therapeutics to be approximately $4.3 billion across the 7MM in 2025. By 2035, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 9.8%, reaching sales of $10.9 billion by the end of the forecast period.

The major drivers of CKD market growth over the forecast period are:

• Continued expansion of glucagon-like peptide-1 (GLP-1) receptor agonists into kidney indications
• Launch of seven oral pipeline agents and six injectable pipeline agents
• Rising global CKD prevalence
• The major barriers that will restrict the growth of the CKD market during the forecast period are:

  • High price of newly launched therapies remains a central constraint
  • Persisting general reluctance of nephrologists and other physicians to adopt new therapies, especially given the sheer number of new mechanisms now competing for a place in treatment algorithms, which complicates positioning and sequencing decisions in practice
  • Widespread use of generic CKD drugs, continuing to limit the penetration of high-priced branded therapies, particularly earlier-line CKD treatments

Reasons to Buy

The report includes an Excel-based forecast model supporting the CKD market outlook through 2035. This can help you assess market development over time and incorporate forecast data into your own commercial, strategic, or financial analysis. The combination of forecast data and qualitative market intelligence provides a broader basis for evaluating CKD market opportunities.

Report Value Proposition: Turn CKD Market Intelligence Into Strategic Action

This report is designed to help you move beyond market size estimates.

It brings together epidemiology, treatment trends, pipeline intelligence, competitive assessment, physician insights, unmet needs, and market forecasts in one analysis.

You can use the findings to:

• Identify potential growth opportunities in CKD
• Assess emerging treatment modalities
• Benchmark competitors and pipeline strength
• Identify potential licensing and partnership opportunities
• Support portfolio and pipeline strategy
• Evaluate market-entry opportunities
• Inform sales and marketing planning
• Understand potential threats from emerging therapies
• Prioritize markets and patient segments
• Support investment and commercial strategy discussions

In addition, the Excel forecast model can provide a practical foundation for further internal analysis.

Who Should Buy This CKD Market Report?

This report is particularly relevant for:

• Pharmaceutical companies
• Biotechnology companies
• Drug developers
• Medical technology and healthcare companies
• Business development and licensing teams
• Corporate strategy teams
• Commercial strategy teams
• Market access teams
• Competitive intelligence teams
• R&D and innovation leaders
• Investment banks
• Private equity and venture capital firms
• Healthcare investors
• Management consultants
• Healthcare market researchers

It is especially relevant to decision-makers responsible for CKD pipeline strategy, market opportunity assessment, competitive intelligence, licensing, investment, and commercial planning.

CKD Competitive Landscape: Benchmark Leading Companies and Emerging Players

The CKD market includes established pharmaceutical companies alongside emerging innovators.

The report assesses current and future competition across the 7MM. It also examines pipeline strength, deal-making trends, market events, and competitive dynamics.

Companies covered include:

• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Eli Lilly
• Johnson & Johnson
• Lexicon Pharmaceuticals
• Novo Nordisk
• CSL
• ProKidney
• Sarfez Pharmaceutical
• Mitsubishi Tanabe

You can use these insights to benchmark your position against established and emerging players.

The analysis may also help you identify potential competitive threats, partnership opportunities, and areas where market positioning could change.

Seven-Market CKD Analysis: Compare the US, Europe and Japan

The report provides market analysis across the US, 5EU and Japan.

For each major market, the analysis examines:

• Market forecast
• Key events
• Market drivers
• Market barriers
• Competitive dynamics

This allows you to understand how the CKD opportunity differs across major pharmaceutical markets.

Therefore, the report can support geographic prioritization and market-specific strategy development.

What You Will Get From This CKD Market Analysis

The report provides a structured view of the CKD market, including:

• 2025–2035 CKD market forecast
• 7MM market analysis
• CKD epidemiology forecast
• Disease prevalence by stage
• Diagnosed and dialysis-dependent populations
• Disease management analysis
• Current treatment landscape
• Unmet needs assessment
• R&D strategy analysis
• Clinical trial considerations
• Pipeline assessment
• Late-stage drug profiles
• Pipeline valuation analysis
• Competitive assessment
• Current and future players
• Deal-making trends
• Physician and KOL insights
• US, 5EU and Japan market outlook
• Excel-based forecast model

Built on GlobalData’s Healthcare Intelligence and Analyst Expertise

GlobalData combines market intelligence, epidemiology, pipeline analysis, and primary research to provide a broader view of the CKD treatment landscape.

The analysis incorporates input from key opinion leaders and prescribers, alongside structured epidemiological and market forecasting.

It is also backed by analysts with deep expertise across healthcare, pharmaceuticals, disease intelligence, and epidemiology.

As a result, you can use the report to bring multiple perspectives together when evaluating CKD market opportunities and risks.

Assess the CKD Market Before the Next Wave of Competition

The CKD treatment landscape is changing as new mechanisms and therapies progress through development.

At the same time, established treatments, generic competition, pricing pressures, and physician adoption may influence the pace of market change.

Therefore, understanding the market outlook, patient population, pipeline, competitive landscape, and unmet needs can help you make better-informed strategic decisions.

Access the CKD market analysis and 2035 forecast to evaluate the opportunities, risks, and competitive dynamics shaping the next phase of CKD treatment.